论文部分内容阅读
目的研究曼月乐对子宫腺肌病患者的临床疗效,以期明确子宫腺肌病的最佳治疗方案,提高患者治疗效果。方法 2012年10月—2013年4月选择武汉大学人民医院收治的子宫腺肌病患者56例做为研究对象,入院后均使用曼月乐治疗,比较放置曼月乐治疗3个月前后患者的子宫内膜厚度、血红蛋白、CA125(carbohydrate antigen 125,CA125)水平、痛经程度、月经量与生活质量。结果放置曼月乐后3个月子宫内膜厚度从(0.77±0.14)cm变为(0.69±0.12)cm,血红蛋白含量从(121.23±6.61)g/L增加至(126.00±5.06)g/L,CA125含量从(40.02±13.74)U/ml降低至(19.75±6.24)U/ml,痛经VRS(Verbal rating scale,VRS)得分降低(0.88±0.69),月经失血图评分减少(24.66±8.97),生命质量测定表得分提高(77.46±12.38),差异均有统计学意义(P<0.01)。结论子宫腺肌病的保守治疗方法仍是医学上的难题,曼月乐具有显著的临床治疗效果,是一种经济安全且不良反应少的保守治疗方法,具有较高的临床推广价值。
Objective To study the clinical efficacy of Mirena in patients with adenomyosis, in order to determine the best treatment of adenomyosis and improve the therapeutic effect of patients. Methods From October 2012 to April 2013, 56 patients with adenomyosis admitted to People’s Hospital of Wuhan University were enrolled in this study. All patients were treated with Mirenael after admission. The patients who were treated with Mirenae for 3 months Endometrial thickness, hemoglobin, carbohydrate antigen 125 (CA125) level, dysmenorrhea, menstrual flow and quality of life. Results The thickness of endometrium was changed from (0.77 ± 0.14) cm to (0.69 ± 0.12) cm and the hemoglobin content increased from (121.23 ± 6.61) g / L to (126.00 ± 5.06) g / L (P <0.05), and the level of CA125 decreased from (40.02 ± 13.74) U / ml to (19.75 ± 6.24) U / ml. The score of VRS decreased (0.88 ± 0.69) and the score of menstrual blood loss decreased (24.66 ± 8.97) (77.46 ± 12.38), the differences were statistically significant (P <0.01). Conclusions Conservative treatment of adenomyosis is still a medical problem. Mirena has a significant effect on clinical treatment. It is a conservative treatment with low cost and safety, and has high clinical value.